Cefaclor (cefaclor)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Cefaclor is a semisynthetic, second generation cephalosporin antibiotic.

Cefaclor is used orally for the treatment of acute otitis media caused by susceptible bacteria; pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A beta-hemolytic streptococci); mild to moderate upper and lower respiratory tract infections (including pneumonia) caused by susceptible bacteria; uncomplicated skin and skin structure infections caused by susceptible bacteria; and urinary tract infections (including pyelonephritis and cystitis) caused by susceptible bacteria. While commercially available cefaclor capsules and oral suspension can be used for any of these infections, safety and efficacy of cefaclor extended-release tablets have been established only for the treatment of mild to moderate respiratory tract infections (i.e., acute exacerbations of chronic bronchitis, secondary infections of acute bronchitis) caused by susceptible bacteria; pharyngitis and tonsillitis caused by S. pyogenes; and mild to moderate uncomplicated skin and skin structure infections caused by susceptible Staphylococcus aureus (methicillin-susceptible (oxacillin-susceptible) strains only).

Generic name: cefaclor
Pronunciation: (SEF-a-klor)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Cefaclor

Intelligence content is not available yet.

Indications

The following indications are listed for Cefaclor:

  • Acute Bacterial Otitis Media
  • Bacterial Urinary Tract Infection
  • Haemophilus Influenzae Pneumonia
  • Lower Respiratory Infection
  • Pharyngitis
  • Pneumonia
  • Skin And Skin Structure Infection
  • Streptococcal Pneumonia
  • Tonsillitis
  • Upper Respiratory Infection

Also known as: Acute Upper Respiratory Tract Infection, Acute Uri, Bacterial Otitis Media, H. Flu Pneumonia, H. Influenzae Pneumonia, Hemophilus Influenzae Pneumonia, Infection Of Skin And/Or Subcutaneous Tissue, Influenza Bacillus Pneumonia, Lower Respiratory Tract Infection, Pfeiffer's Bacillus Pneumonia, Pneumonia Due To Haemophilus Influenzae, Pneumonia Due To Streptococcus Species, Pneumonia Due To Streptococcus Spp., Skin And Soft Tissue Skin Infection, Throat Inflammation.

Dosing

Cefaclor is commercially available as the monohydrate; dosage is expressed in terms of anhydrous cefaclor.

Modification of usual cefaclor dosage is not necessary in patients with renal impairment; however, close clinical observation and appropriate laboratory tests are recommended in patients with moderate or severe renal impairment since experience in such patients is limited.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data